Pediatric Oncology Department, University Hospital Brno, Masaryk University Brno, Brno, Czech Republic.
Pediatr Blood Cancer. 2010 Apr;54(4):616-7. doi: 10.1002/pbc.22382.
Prognosis for children with relapsed medulloblastoma remains poor. Metronomic chemotherapy may offer some benefit to patients treated initially with intensive regimens. However, dosing and duration of such palliative treatment have not been systematically studied. Here we describe a child with medulloblastoma relapsing after initial high-dose chemotherapy and standard radiotherapy. The patient was then treated with metronomic chemotherapy and achieved second complete remission after 21 months of treatment. Three months off therapy he relapsed again and died from progressive disease. This case illustrates the potential benefit of metronomic chemotherapy but also shows the uncertainty of when to stop metronomic chemotherapy while balancing toxicity.
患有复发性髓母细胞瘤的儿童预后仍然较差。节拍化疗可能对最初接受强化治疗方案治疗的患者有一定益处。然而，这种姑息性治疗的剂量和持续时间尚未得到系统研究。在此，我们描述了一名患有髓母细胞瘤的儿童，该患者在初始接受大剂量化疗和标准放疗后复发。随后，该患者接受了节拍化疗，并在治疗 21 个月后获得了第二次完全缓解。停止治疗 3 个月后，他再次复发，并死于疾病进展。该病例说明了节拍化疗的潜在益处，但也表明了在权衡毒性的情况下，何时停止节拍化疗存在不确定性。
